Teduglutide in short bowel syndrome patients: A way back to normal life?

• Published in: JPEN. Journal of parenteral and enteral nutrition Vol. 46; no. 2; pp. 300 - 309
• Main Authors: Harpain, Felix, Schlager, Lukas, Hütterer, Elisabeth, Dawoud, Christopher, Kirchnawy, Sabine, Stift, Judith, Krotka, Pavla, Stift, Anton
• Format: Journal Article
• Language: English
• Published: United States 01.02.2022
• Subjects: enteral autonomy; Gastrointestinal Agents - therapeutic use; glucagon‐like peptide 2; Humans; intestinal failure; Peptides - therapeutic use; Retrospective Studies; short bowel syndrome; Short Bowel Syndrome - drug therapy; Short Bowel Syndrome - pathology; teduglutide; Treatment Outcome; glucagon-like peptide 2; intestinal failure; enteral autonomy; short bowel syndrome; teduglutide
• ISSN: 0148-6071; 1941-2444
• DOI: 10.1002/jpen.2272

Background The glucagon‐like peptide 2 analogue teduglutide is an effective drug for the treatment of short bowel syndrome patients with intestinal failure (SBS‐IF). This intestinotrophic peptide improves intestinal capacity for fluid and nutrient absorption through induction of mucosal growth and reduction of gastrointestinal motility. Clinical trials demonstrated the efficacy of teduglutide in reducing the need for parenteral support (PS). This study describes an SBS‐IF patient population receiving teduglutide therapy in a specialized medical care setting. Method A retrospective analysis was performed using data of patients experiencing nonmalignant SBS‐IF. They were treated with teduglutide in a multidisciplinary SBS‐IF program at a single university medical center between June 2016 and June 2020. Results Thirteen patients under teduglutide treatment were included in the final analysis. Mean small bowel length was 82 ± 31 cm, with 77% of patients having their colon in continuity. Over a median follow‐up of 107 weeks, all patients (13 of 13, 100%) responded to the therapy with a clinically significant reduction of PS volume. Mean PS reduction increased with therapy duration and ranged from −82.5% at week 24 (n = 13) to −100% in patients (n = 5) who were treated for 144 weeks. Enteral autonomy was achieved in 12 of 13 (92%) patients. Teduglutide therapy improved stool frequency and consistency, changed dietary habits, and reduced disease‐associated sleep disruptions. Conclusion Integrating SBS‐IF patients treated with teduglutide in a proactive and tight‐meshed patient care program significantly improves the clinical outcome, leading to an increased proportion of patients reaching enteral autonomy.